Ticagrelor versus clopidogrel or aspirin in transient ischemic attack (TIA) or ischemic stroke: a systematic review and meta-analysis

Read full text Summarise with VIRAT
Authors: Hussain Ali Almohammed, Bayan Mohammed Khair Al Zoabi, Husna Irfan Thalib, Lamees Abdulmohsen Alhajri, Jakleen Ziyad Abujamai, Rimas Warid Aljuaid, Jory H. Alzahrani, Jana M. Alsyrwan, Mohammed Fadhel Alwabari, Nawaf Abdullah Alghafli, Saud A. Alnaaim
Cited by: 0
References: 32

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background A transient ischemic attack (TIA) or ischemic stroke often signals a high risk of another event, especially in the days following. While aspirin and clopidogrel are standard treatments, their limitations, such as genetic resistance to clopidogrel, have led to interest in ticagrelor as an alternative. We aimed to address this by comparing the efficacy and safety of ticagrelor (either as monotherapy or in combination with aspirin) with those of aspirin or clopidogrel. Methods This systematic review and meta-analysis adhered to the 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The PubMed, Web of Science, and Cochrane databases were comprehensively searched to identify randomized controlled trials comparing ticagrelor alone or with aspirin versus aspirin, clopidogrel, or clopidogrel plus aspirin. Odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model. Results This study included 32,782 patients with ischemic stroke or TIA. Ticagrelor-based regimens lowered the risk of ischemic stroke (OR = 0.81; 95% CI: 0.75–0.88), with the strongest benefit observed with clopidogrel alone. Composite vascular events were also reduced (OR = 0.78; 95% CI: 0.68–0.89), particularly with ticagrelor plus aspirin. However, ticagrelor increased the risk of bleeding (OR = 2.04; 95% CI: 1.63–2.55), fatal bleeding (OR = 2.22; 95% CI: 1.02–4.79), and hemorrhagic stroke (OR = 1.53; 95% CI: 1.02–2.30). Conclusions Early initiation of ticagrelor after TIA or ischemic stroke can significantly reduce recurrent vascular events, particularly in patients with clopidogrel resistance. However, this benefit comes with a higher risk of serious bleeding, underscoring the importance of careful patient selection and individualized treatment planning.

Fields of Study & Subjects

Antiplatelet Therapy and Cardiovascular Diseases Acute Ischemic Stroke Management Blood Coagulation and Thrombosis Mechanisms

Publication details

Journal / source
The Egyptian Journal of Neurology Psychiatry and Neurosurgery
Volume
62
Issue
1
Publication date
25 March 2026
Language
EN